The Female Health Company To Present At 15th Annual B. Riley & Co. Investor Conference On May 19, 2014

News provided by

May 12, 2014, 08:30 ET

CHICAGO, May 12, 2014 /PRNewswire/ -- The Female Health Company (Nasdaq-CM: FHCO) today announced that it will be presenting at the 15^th Annual B. Riley & Co. Investor Conference on May 19, 2014.

The conference is being held at the Loews Santa Monica Beach Hotel, which is located at 1700 Ocean Avenue in Santa Monica, California.

The presentation by Karen King, Chief Executive Officer, and Michele Greco, Chief Financial Officer, is scheduled for 10:30 a.m. PDT (1:30 p.m. EDT) on Monday, May 19, 2014.

Management will be available to meet with investors throughout the day. Portfolio managers and analysts who wish to request a meeting with the Company should contact their B. Riley & Co. representative.

About the B. Riley & Co. Investor Conference

The prestigious three-day, invitation-only annual B. Riley & Co. Investor Conference brings together a targeted audience of leading institutional investors, financial services professionals and other qualified investors. The conference will feature presentations by approximately 200 companies in a broad range of sectors, including technology, consumer, retail, energy, healthcare, media and entertainment and special situations. One-on-one meetings with company managements will be available for all client investors.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, it has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by the FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].

Logo - http://photos.prnewswire.com/prnh/20120712/MM39764LOGO

SOURCE The Female Health Company